loading

Context Therapeutics Inc 주식(CNTX)의 최신 뉴스

pulisher
07:41 AM

Context Therapeutics Inc. Advances CTIM-76 in Phase 1 Trial for Solid Tumors with Initial Data Expected in 2026 - Nasdaq

07:41 AM
pulisher
07:32 AM

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting - GlobeNewswire

07:32 AM
pulisher
07:30 AM

Context Therapeutics' Cancer Drug CTIM-76 Progresses in Phase 1 Trial: Key Updates from ASCO 2025 - Stock Titan

07:30 AM
pulisher
May 30, 2025

Context Therapeutics names new CMO to advance T cell therapies By Investing.com - Investing.com South Africa

May 30, 2025
pulisher
May 29, 2025

Context Therapeutics Names Dr. Karen Chagin as Chief Medical Officer - MyChesCo

May 29, 2025
pulisher
May 29, 2025

Context Therapeutics (CNTX) Names New Chief Medical Officer | CN - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Context Therapeutics (CNTX) Names New Chief Medical Officer | CNTX Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Context Therapeutics names new CMO to advance T cell therapies - Investing.com

May 29, 2025
pulisher
May 29, 2025

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

Context Therapeutics Appoints Developer of First FDA-Approved Solid Tumor Cell Therapy as Chief Medical Officer - Stock Titan

May 29, 2025
pulisher
May 18, 2025

Context Therapeutics Grants Stock Options to New Hires as Part of Strategic Talent Growth - MSN

May 18, 2025
pulisher
May 17, 2025

Context Therapeutics Names Dr. Karen Smith as Interim Chief Medical Officer - MSN

May 17, 2025
pulisher
May 16, 2025

Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.40 Consensus Price Target from Analysts - Defense World

May 16, 2025
pulisher
May 15, 2025

Context Therapeutics Reports Q1 2025 Financial Results and Clinical Progress - MSN

May 15, 2025
pulisher
May 12, 2025

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 12, 2025
pulisher
May 12, 2025

William Blair Has Positive Outlook of CNTX FY2025 Earnings - Defense World

May 12, 2025
pulisher
May 12, 2025

Research Analysts Offer Predictions for CNTX Q2 Earnings - Defense World

May 12, 2025
pulisher
May 10, 2025

D. Boral Capital Reaffirms “Buy” Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World

May 10, 2025
pulisher
May 09, 2025

UTR Therapeutics files IND application for UTRxM1-18 for c-MYC-driven cancers - BioWorld MedTech

May 09, 2025
pulisher
May 08, 2025

Context Therapeutics Showcases Promising CT-95 Data at AACR Annual Meeting - MSN

May 08, 2025
pulisher
May 08, 2025

Context Therapeutics (CNTX) Receives Continued 'Buy' Rating from Analyst | CNTX Stock News - GuruFocus

May 08, 2025
pulisher
May 07, 2025

FORE Biotherapeutics’ Plixorafenib Study to Be Highlighted at ASCO 2025 - MyChesCo

May 07, 2025
pulisher
May 07, 2025

CONTEXT THERAPEUTICS Earnings Results: $CNTX Reports Quarterly Earnings - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results - GlobeNewswire

May 07, 2025
pulisher
May 06, 2025

Marshall Wace LLP Buys New Stake in Context Therapeutics Inc. (NASDAQ:CNTX) - The AM Reporter

May 06, 2025
pulisher
May 05, 2025

Context Therapeutics Appoints Karen Smith as Interim CMO - citybiz

May 05, 2025
pulisher
May 05, 2025

Context Therapeutics (CNTX) Names Karen Smith as Interim Chief Medical Officer | CNTX Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Context Therapeutics appoints new interim CMO - Investing.com

May 05, 2025
pulisher
May 05, 2025

Context Therapeutics appoints new interim CMO By Investing.com - Investing.com South Africa

May 05, 2025
pulisher
May 05, 2025

Context Therapeutics Announces Chief Medical Officer Transition - GlobeNewswire

May 05, 2025
pulisher
May 05, 2025

Context Therapeutics Inc Announces Executive Changes Effective May 10, 2025 - marketscreener.com

May 05, 2025
pulisher
May 05, 2025

Renaissance Technologies LLC Boosts Stock Holdings in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World

May 05, 2025
pulisher
May 02, 2025

What is William Blair’s Estimate for CNTX Q2 Earnings? - Defense World

May 02, 2025
pulisher
May 02, 2025

Context Therapeutics Inc. (NASDAQ:CNTX) Stock Holdings Boosted by Geode Capital Management LLC - Defense World

May 02, 2025
pulisher
May 02, 2025

Context Therapeutics’ (CNTX) Outperform Rating Reiterated at William Blair - Defense World

May 02, 2025
pulisher
May 02, 2025

Context Therapeutics’ (CNTX) Buy Rating Reiterated at D. Boral Capital - Defense World

May 02, 2025
pulisher
May 01, 2025

Q1 Earnings Forecast for CNTX Issued By William Blair - Defense World

May 01, 2025
pulisher
Apr 30, 2025

Context Therapeutics reports progress in cancer treatment By Investing.com - Investing.com India

Apr 30, 2025
pulisher
Apr 30, 2025

Context Therapeutics (CNTX) Presents Promising Data on CT-95 at AACR 2025 | CNTX Stock News - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Context Therapeutics reports progress in cancer treatment - Investing.com

Apr 30, 2025
pulisher
Apr 30, 2025

Context Therapeutics Inc. Announces Preclinical Data Supporting Unique Binding Mechanism of CT-95 and Progress in Phase 1 Clinical Trial - Nasdaq

Apr 30, 2025
pulisher
Apr 30, 2025

Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting - GlobeNewswire

Apr 30, 2025
pulisher
Apr 30, 2025

Breakthrough Cancer Treatment CT-95 Reveals Unique Binding Mechanism in Multiple Tumor Types - Stock Titan

Apr 30, 2025
pulisher
Apr 24, 2025

Q1 Earnings Estimate for CNTX Issued By William Blair - Defense World

Apr 24, 2025
$1.0846
price down icon 1.76%
$29.97
price down icon 0.70%
$577.79
price up icon 0.89%
$306.27
price up icon 0.67%
$4.47
price down icon 2.22%
$489.50
price down icon 0.11%
자본화:     |  볼륨(24시간):